/images/ppid_59c68470-image-177918268118487942.webp)
/images/ppid_59c68470-image-177909518904794041.webp)
/images/ppid_59c68470-image-177892509264380356.webp)
What is the story about?
Strides Pharma Science Ltd. said it expects growth recovery in its US business from the second half of FY27, while maintaining its North America revenue aspiration of $375–400 million by FY28 despite a weaker-than-expected flu season impacting recent quarters.
Speaking during the post-earnings conference call, the company's management said the flu season in the US was weaker than expected, which weighed on demand and impacted year-on-year growth in the company’s North America business.
US revenue for the fourth quarter stood at $70 million, flat sequentially and lower than the $77 million reported in the year-ago quarter. For the full year, US revenue came in at $284 million compared to $291 million in FY25.
The company, however, reiterated its long-term North America revenue target of $375–400 million by FY28 and said growth is expected to recover from H2FY27 onwards.
In contrast, the Ex-US business continued to emerge as the key growth driver for the company.
Ex-US revenue rose to $70 million in the fourth quarter from $64 million in the previous quarter and $57 million a year ago. The contribution of Ex-US markets to overall sales increased to 46% in FY26 from 41% in FY24.
The management said Ex-US markets are expected to grow faster than the US business going ahead, supported by strong momentum across key geographies.
The company also said EBITDA margins improved to around 19% during FY26 and reiterated its guidance of achieving 20%-plus margins ahead.
The commentary comes after Strides Pharma reported a consolidated net profit of ₹129.2 crore for the fourth quarter, up 51% year-on-year from ₹86 crore in the corresponding quarter last year.
Revenue for the quarter rose 11.2% to ₹1,323.4 crore from ₹1,190.3 crore a year ago, while EBITDA increased 10% to ₹239.6 crore from ₹218 crore.
For FY26, Ex-US market revenue rose 21% year-on-year to ₹2,240.4 crore, while US market revenue grew 2% to ₹2,489.7 crore.
Managing Director and Group CEO Badree Komandur said the company delivered strong profitability and efficiency metrics during FY26, driven by robust momentum in Ex-US markets.
The board has recommended a final dividend of ₹5 per equity share for FY26.
Shares of Strides Pharma reacted to the results announced after market hours on Monday, falling sharply to hit an intraday low of ₹1,035 on Tuesday morning. The stock is now off the day's lows and was trading at ₹1,117, still about 3% lower. It has, however, gained 12% over the past month and 63% in the last year.
Speaking during the post-earnings conference call, the company's management said the flu season in the US was weaker than expected, which weighed on demand and impacted year-on-year growth in the company’s North America business.
US revenue for the fourth quarter stood at $70 million, flat sequentially and lower than the $77 million reported in the year-ago quarter. For the full year, US revenue came in at $284 million compared to $291 million in FY25.
The company, however, reiterated its long-term North America revenue target of $375–400 million by FY28 and said growth is expected to recover from H2FY27 onwards.
In contrast, the Ex-US business continued to emerge as the key growth driver for the company.
Ex-US revenue rose to $70 million in the fourth quarter from $64 million in the previous quarter and $57 million a year ago. The contribution of Ex-US markets to overall sales increased to 46% in FY26 from 41% in FY24.
The management said Ex-US markets are expected to grow faster than the US business going ahead, supported by strong momentum across key geographies.
The company also said EBITDA margins improved to around 19% during FY26 and reiterated its guidance of achieving 20%-plus margins ahead.
The commentary comes after Strides Pharma reported a consolidated net profit of ₹129.2 crore for the fourth quarter, up 51% year-on-year from ₹86 crore in the corresponding quarter last year.
Revenue for the quarter rose 11.2% to ₹1,323.4 crore from ₹1,190.3 crore a year ago, while EBITDA increased 10% to ₹239.6 crore from ₹218 crore.
For FY26, Ex-US market revenue rose 21% year-on-year to ₹2,240.4 crore, while US market revenue grew 2% to ₹2,489.7 crore.
Managing Director and Group CEO Badree Komandur said the company delivered strong profitability and efficiency metrics during FY26, driven by robust momentum in Ex-US markets.
The board has recommended a final dividend of ₹5 per equity share for FY26.
Shares of Strides Pharma reacted to the results announced after market hours on Monday, falling sharply to hit an intraday low of ₹1,035 on Tuesday morning. The stock is now off the day's lows and was trading at ₹1,117, still about 3% lower. It has, however, gained 12% over the past month and 63% in the last year.
/images/ppid_59c68470-image-177909756706135116.webp)
/images/ppid_59c68470-image-17791200462387222.webp)
/images/ppid_59c68470-image-17790825254491354.webp)
/images/ppid_59c68470-image-177911254107236889.webp)
/images/ppid_59c68470-image-17790950207371920.webp)
/images/ppid_59c68470-image-177907256077941626.webp)
/images/ppid_59c68470-image-177908752846313781.webp)
/images/ppid_59c68470-image-177911753128770668.webp)